UC Davis Health Clinical Studies

A Study of Experimetnal VarIthena on Wound Healing in Venous Leg Ulcers (VLU)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The purpose of this registry is to look at how experimental Varithena® injectable foam works. It will be given to patients who have chronic venous insufficiency (commonly known as “varicose veins”) with leg wounds. The decision to provide you with such medication has been left up to your treating physician and is not being driven by or impacted by this study. The purpose of this project is to collect data about your leg wounds. We hope to learn the impact of treatment on the rate of healing, the rate of repeated wounds, as well as the impacts to your level of pain and quality of life.

Drug study
Any, age 18 years or older

A Study of Experimental Magnesium Infusion for Pain Management in Critically Ill Trauma Patients

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

Magnesium is a naturally occurring mineral that is important for your body and brain. Magnesium sulfate (study drug) is a medication containing magnesium. It is commonly used to improve low blood levels of magnesium. Magnesium sulfate has also proven to be successful in managing pain before and after surgery. This drug has primarily been used for pain control in patients undergoing surgery. Patients in the ICU with injuries also need good pain control. Using magnesium may decrease the need for narcotics (pain relievers). It may also provide another non-narcotic drug for pain control. The purpose of this study is to test the effectiveness of continuous, intravenous (into or within a vein using a needle) administration of magnesium sulfate. This will be compared to intravenous normal saline (salt solution).

Drug study, Phase 4
Any, age 18 years or older

A Study of Virtual Museum-Based Experiences to Reduce Social Isolation and Pain

Can participating in virtual museum programs help individuals with chronic pain feel more socially connected? Help us find out!

This research study will develop and evaluate virtual museum-based programs. These programs will aim to address loneliness and social isolation among individuals with chronic pain. Over 100 million American adults suffer from chronic pain. This is more than those with heart disease, cancer, and diabetes combined. Chronic pain is complex. It affects the body, the mind, and social interactions. Previous studies show that social disconnection can cause pain to feel more intense. Studies also show that social connection can help decrease the intensity of pain. Museums may be able to reduce isolation and give people a sense of social connection. We hope to learn if virtual museum engagement in individuals with chronic pain can decrease feelings of social disconnection and the unpleasantness of chronic pain.

Other Study
Any, age 18+

A Study of the Safety and Effectiveness of Experimental Lonafarnib / Ritonavir for Chronic Hepatitis D Virus Infection

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study is for patients with chronic (long-lasting) hepatitis D virus (HDV) infection. Potential participants must be taking or be willing to begin taking nucleotide/nucleoside inhibitors (entecavir or tenofovir). These nucleotide/nucleoside inhibitors must be taken for at least 12 weeks to 6 months before beginning the study treatment. The purpose of this study is to determine whether the study drugs will reduce the amount of HDV in your blood. Other purposes of this study are: - to determine the effects of the study drugs on your liver - to determine if taking the study drugs makes your quality of life better - to evaluate the safety of the study drugs The Sponsor is conducting this study to find new treatments for HDV. This research study is designed to learn more about an investigational drug called lonafarnib. It is being developed to treat chronic HDV infection as well as other conditions. "Investigational" means lonafarnib is not yet approved by the FDA for prescription or over the-counter (OTC) use. Lonafarnib will be taken in combination with an approved drug called ritonavir. Ritonavir is commonly used in the treatment of hepatitis C at comparable dosing to what will be used in this study. In this study, ritonavir is used as a “booster” to increase the amount of lonafarnib in your body. A “booster” is a drug that prevents your body from breaking down lonafarnib, so it can work longer. Some patients in this study will take an interferon medicine approved for treating HBV and hepatitis C virus (HCV) infections. This medicine is called peginterferon-alfa-2a (abbreviated as PEG IFN-alfa-2a). PEG IFN-alfa-2a will be a potential added medicine in this study. We hope to determine if it improves the treatment outcome when taken with lonafarnib and ritonavir. Peginterferon-alfa-2a is a solution that is injected under the skin once per week.

Drug study, Phase 3
Any, age 18 years or older